Arctic Vision Announces Deal to Integrate MDCO Technology’s Ophthalmic Device Business to Form a Global Drug–Device Innovation Platform

February 2, 2026 - 09:48

A significant strategic move is reshaping the global ophthalmic landscape. Arctic Vision, a Shanghai-based global ophthalmic company, has entered into a definitive agreement to integrate the innovative ophthalmic device business of Hangzhou's MDCO Technology. This acquisition is designed to create a comprehensive global platform dedicated to pioneering drug-device combination therapies.

The transaction will see MDCO Technology's portfolio of premium ophthalmic devices, including its intraocular lens (IOL) and implantable contact lens (Phakic Lens) platforms, as well as its refractive-device technology, become part of Arctic Vision's operations. This integration aims to merge Arctic Vision's expertise in pharmaceutical development with cutting-edge medical device capabilities.

Industry analysts view the deal as a forward-looking step to address complex eye diseases through synergistic solutions. By combining forces, the new platform seeks to accelerate the development and delivery of next-generation treatments that integrate therapeutic agents with advanced delivery systems or surgical implants. The move is expected to enhance research pipelines and provide more holistic treatment options for patients worldwide, positioning the combined entity at the forefront of ophthalmic innovation. Financial terms of the agreement were not immediately disclosed.